Aptose Biosciences Inc.
APS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.50% | 86.74% | 39.26% | 48.67% | 29.51% |
| Total Depreciation and Amortization | -9.17% | -11.82% | -13.51% | -10.53% | -16.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.03% | -222.24% | -99.65% | -63.67% | -55.24% |
| Change in Net Operating Assets | 170.40% | -384.97% | -1,678.92% | 443.53% | -971.95% |
| Cash from Operations | 76.24% | 12.95% | 1.52% | 57.21% | -4.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 203.16% | 32.70% |
| Cash from Investing | -- | -100.00% | -- | 202.50% | 32.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.00% | -- | 103.95% | 344.63% | 23,594.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 1,460.00% | -- | -3,440.00% | -- |
| Cash from Financing | -93.00% | 696.84% | 104.16% | 330.62% | 23,594.00% |
| Foreign Exchange rate Adjustments | 100.00% | -- | -- | 66.67% | -75.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.04% | 80.60% | -105.03% | 106.85% | 86.59% |